U.S. Markets close in 4 hrs 50 mins
  • S&P 500

    4,476.31
    +4.94 (+0.11%)
     
  • Dow 30

    35,252.11
    -42.65 (-0.12%)
     
  • Nasdaq

    14,940.79
    +43.45 (+0.29%)
     
  • Russell 2000

    2,264.77
    -0.89 (-0.04%)
     
  • Gold

    1,771.10
    +2.80 (+0.16%)
     
  • EUR/USD

    1.1598
    -0.0003 (-0.0232%)
     
  • 10-Yr Bond

    1.5860
    +0.0670 (+4.41%)
     
  • Vix

    16.79
    +0.49 (+3.01%)
     
  • GBP/USD

    1.3712
    +0.0035 (+0.2578%)
     
  • USD/JPY

    114.2970
    +0.6200 (+0.5454%)
     
  • BTC-USD

    62,002.54
    +1,146.23 (+1.88%)
     
  • CMC Crypto 200

    1,446.02
    -5.61 (-0.39%)
     
  • FTSE 100

    7,199.44
    -34.59 (-0.48%)
     
  • Nikkei 225

    29,025.46
    +474.56 (+1.66%)
     

Amgen Reveals Post-Hoc Data For Its KRAS Inhibitor In Lung Cancer Patients

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Amgen Inc (NASDAQ: AMGN) announced results from two analyses of the Phase 2 CodeBreaK 100 trial evaluating Lumakras (sotorasib).

  • Lumakras, a KRASG12C inhibitor, is approved in the U.S. for previously treated patients with advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC).

  • Related Content: Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer.

  • In a post-hoc analysis of 40 patients, Lumakras achieved a 77.5% disease control rate (DCR), similar to patients without brain metastases.

  • A median progression-free survival (PFS) of 5.3 months and median overall survival (OS) of 8.3 months were observed.

  • In patients evaluable by Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria, 14 of 16 patients (88%) maintained intracranial disease control of their stable brain lesions during Lumakras therapy with two achieving complete responses of non-target lesions.

  • The safety profile of Lumakras in the brain metastases group was consistent with previous reports.

  • Amgen is enrolling patients with active brain metastases in an arm of the CodeBreaK 101 study.

  • Price Action: AMGN stock is down 0.41% at $219.97 during the premarket session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.